Can-Fite BioPharma Ltd. (TLV: CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA1.700
-0.100 (-5.56%)
Dec 19, 2024, 5:24 PM IDT
Can-Fite BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 4.72 | 4.28 | 2.98 | 4.39 | 8.27 | 2.7 | Upgrade
|
| Short-Term Investments | 0.01 | 4.63 | 5 | 14.51 | - | - | Upgrade
|
| Trading Asset Securities | - | 0.02 | 0.01 | 0.24 | 0.08 | 0.06 | Upgrade
|
| Cash & Short-Term Investments | 4.73 | 8.92 | 7.99 | 19.14 | 8.34 | 2.76 | Upgrade
|
| Cash Growth | -50.83% | 11.71% | -58.27% | 129.40% | 202.17% | -28.99% | Upgrade
|
| Other Receivables | - | - | - | - | - | 0.65 | Upgrade
|
| Receivables | - | - | - | - | - | 0.65 | Upgrade
|
| Prepaid Expenses | 1.1 | 0.91 | 1.12 | 0.88 | 1.04 | 3.73 | Upgrade
|
| Other Current Assets | - | 0.08 | 0.05 | 0.05 | 0.02 | - | Upgrade
|
| Total Current Assets | 5.83 | 9.91 | 9.16 | 20.07 | 9.4 | 7.14 | Upgrade
|
| Property, Plant & Equipment | 0.09 | 0.08 | 0.13 | 0.19 | 0.12 | 0.12 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | - | 0.91 | Upgrade
|
| Total Assets | 5.92 | 9.99 | 9.28 | 20.25 | 9.52 | 8.17 | Upgrade
|
| Accounts Payable | 0.89 | 0.43 | 0.9 | 0.95 | 0.56 | 2.16 | Upgrade
|
| Accrued Expenses | 0.43 | 0.94 | 0.78 | 0.91 | 0.33 | - | Upgrade
|
| Current Portion of Leases | 0.04 | 0.03 | 0.05 | 0.05 | 0.04 | 0.04 | Upgrade
|
| Current Unearned Revenue | 0.64 | 0.62 | 0.78 | 0.82 | 0.33 | 0.47 | Upgrade
|
| Other Current Liabilities | - | - | - | - | - | 0.61 | Upgrade
|
| Total Current Liabilities | 1.99 | 2.02 | 2.5 | 2.73 | 1.27 | 3.27 | Upgrade
|
| Long-Term Leases | 0.02 | 0.01 | 0.01 | 0.07 | 0.02 | 0.04 | Upgrade
|
| Long-Term Unearned Revenue | 1.44 | 1.71 | 2.3 | 3.07 | 2.16 | 2.42 | Upgrade
|
| Total Liabilities | 3.44 | 3.75 | 4.81 | 5.87 | 3.45 | 5.73 | Upgrade
|
| Common Stock | - | - | - | - | 33.04 | 8.23 | Upgrade
|
| Additional Paid-In Capital | 163.79 | 163.6 | 154.19 | 153.93 | 97.38 | 103.4 | Upgrade
|
| Retained Earnings | -162.44 | -158.48 | -150.85 | -140.67 | -125.47 | -110.31 | Upgrade
|
| Comprehensive Income & Other | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | Upgrade
|
| Total Common Equity | 2.48 | 6.24 | 4.47 | 14.38 | 6.07 | 2.44 | Upgrade
|
| Shareholders' Equity | 2.48 | 6.24 | 4.47 | 14.38 | 6.07 | 2.44 | Upgrade
|
| Total Liabilities & Equity | 5.92 | 9.99 | 9.28 | 20.25 | 9.52 | 8.17 | Upgrade
|
| Total Debt | 0.06 | 0.04 | 0.06 | 0.12 | 0.07 | 0.08 | Upgrade
|
| Net Cash (Debt) | 4.67 | 8.88 | 7.93 | 19.02 | 8.28 | 2.69 | Upgrade
|
| Net Cash Growth | -51.09% | 12.08% | -58.32% | 129.76% | 208.12% | -30.92% | Upgrade
|
| Net Cash Per Share | 0.00 | 0.01 | 0.01 | 0.03 | 0.02 | 0.03 | Upgrade
|
| Filing Date Shares Outstanding | 1,672 | 1,497 | 1,225 | 815.75 | 515.75 | 263.18 | Upgrade
|
| Total Common Shares Outstanding | 1,672 | 1,360 | 815.75 | 815.75 | 463.77 | 120.65 | Upgrade
|
| Working Capital | 3.84 | 7.89 | 6.66 | 17.34 | 8.13 | 3.87 | Upgrade
|
| Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | Upgrade
|
| Tangible Book Value | 2.48 | 6.24 | 4.47 | 14.38 | 6.07 | 2.44 | Upgrade
|
| Tangible Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | Upgrade
|
| Machinery | - | 0.28 | 0.28 | 0.27 | 0.26 | 0.23 | Upgrade
|
| Leasehold Improvements | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.